Rock Springs Capital Management LP Prometheus Biosciences, Inc. Transaction History

Rock Springs Capital Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$36.06 - $117.21 $13.9 Million - $45.3 Million	386,143 Added 59.83%	1,031,550 $113 Million
Q3 2022 Nov 14, 2022	BUY	$28.17 - $59.01 $25,353 - $53,109	900 Added 0.14%	645,407 $38.1 Million
Q2 2022 Aug 15, 2022	BUY	$22.39 - $38.94 $452,278 - $786,588	20,200 Added 3.24%	644,507 $18.2 Million
Q1 2022 May 16, 2022	BUY	$30.13 - $50.0 $177,767 - $295,000	5,900 Added 0.95%	624,307 $23.6 Million
Q4 2021 Feb 14, 2022	BUY	$22.28 - $39.54 $184,277 - $327,035	8,271 Added 1.36%	618,407 $24.5 Million
Q3 2021 Nov 15, 2021	BUY	$20.89 - $26.96 $293,295 - $378,518	14,040 Added 2.36%	610,136 $14.5 Million
Q2 2021 Aug 16, 2021	BUY	$16.8 - $29.65 $356,798 - $629,706	21,238 Added 3.69%	596,096 $14.6 Million
Q1 2021 May 17, 2021	BUY	$16.51 - $25.29 $9.49 Million - $14.5 Million	574,858 New	574,858 $10.5 Million

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Rock Springs Capital Management LP with notifications on news.